Brind.
  1. Vivos is advancing its product line by securing patents via USPTO filings and gaining unprecedented 510K clearances for an alternative to CPAP technology.

Vivos Acquires Equity and Patents from SOD Sciences for $12 Million

2 reports, 1 independent Updated Thu 00:00
No new developments lately Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Vivos closed a strategic partnership with SOD Sciences on October 26, 2026. Vivos acquired an 11% equity interest in SOD Sciences, along with 50% ownership of SOD's pseudohypoxia patent and 50% ownership of the ReBalU Primed Cell Test. The acquisition was made in exchange for $12 million of Vivos Series D Convertible Preferred Stock.

From californiatelegraph.com

Why it matters

Some supportBrind's analysis of the reports

The acquisition expands Vivos' intellectual property portfolio. SOD Sciences' ReBalU Protocol is built on the principle that chronic diseases stem from antioxidant system imbalances, a condition that accounts for 90% of the nation's $5.3 trillion in annual health care spending.

Vivos is advancing its product line by securing patents through USPTO filings and gaining 510K clearances for an alternative to CPAP technology.

From californiatelegraph.com

Who's involved

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • VivosSpeculative

    Vivos could increase its revenue potential by integrating strategic assets and patents from SOD Sciences.

Keep exploring

The entities involved

  • Vivos

    California-based company, that provdes hardened underground shelters designed to withstand future disasters and life-extinction catastrophes

    Nothing else this week.

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story